Key result
Clopidogrel fails to alter thrombin generation in healthy dogs despite achieving platelet inhibition.
Why the study?
Clopidogrel's antiplatelet effect varies between patients, and while TEG-PM can monitor it, it is not widely available, making thrombin generation assays a potential novel alternative.
Does clopidogrel administration reduce thrombin generation assay variables in healthy dogs?
Does clopidogrel administration reduce thrombin generation assay variables in healthy dogs?
Thrombin generation assays performed on platelet poor plasma do not reflect the antiplatelet effects of clopidogrel in dogs, despite concurrent evidence of platelet inhibition on TEG-PM.
Answers are grounded in this paper and cite their sources.
TG assays on platelet-poor plasma miss clopidogrel's antiplatelet effects in dogs; leaves open their monitoring utility in veterinary cardiology.
Introduction The antiplatelet effect of clopidogrel can vary between patients. A modified thromboelastography (TEG) protocol (TEG-Platelet Mapping assay ® [TEG-PM]) can be used for clopidogrel monitoring but is not widely available. Thrombin generation (TG) assays could offer a novel alternative. The main objective of this pilot study was to assess TG assay variables (lag time, peak, endogenous thrombin potential [ETP]) in dogs before and after 7 days of clopidogrel administration and compare with TEG-PM variables (maximum amplitude [MA]-ADP and percentage (%) inhibition). Methods Six healthy mix-breed dogs were enrolled in this pilot study. Blood samples for platelet count, TG assays, and TEG-PM were obtained at two time points, corresponding to baseline, and after 7 days of clopidogrel administration (mean 2.3 +/− 0.3 mg/kg PO q24 hours). Data were then compared with a Student’s t -test. Results There was no significant change in TG assay variables performed on platelet poor plasma after 7 days of clopidogrel administration: lag time (Day 1: 1.8 +/− 0.2 min, Day 7: 1.8 +/− 0.2 min, p = 0.42); peak (Day 1: 76 +/− 7 nM, Day 7: 72 +/− 10 nM, p = 0.49); and ETP (Day 1: 399 +/− 27 nM*min, Day 7: 392 +/− 32 nM*min; p = 0.49). There were significant changes in TEG MA-ADP (Day 1: 19 +/− 8 mm, Day 7: 9 +/− 6 mm, p = 0.04) and % inhibition (Day 1: 58 +/− 27, Day 7: 99 +/− 0.3, p = 0.02). Discussion Clopidogrel administration did not lead to changes in TG assay variables performed on platelet poor plasma samples, despite concomitant changes in TEG-PM variables consistent with platelet inhibition. Based on this pilot study, thrombin generation performed on platelet poor plasma may not be a useful antiplatelet monitoring tool in dogs.
No takes yet. Share an insight, caveat, or question.
Rank et al. (2023) studied Healthy (n=6). Clopidogrel vs. Baseline (pre-treatment) was evaluated on Endogenous thrombin potential (ETP) (p=0.49). Clopidogrel administration for 7 days did not significantly change thrombin generation assay variables in healthy dogs, despite concomitant changes in TEG-PM variables consistent with platelet inhibition.
Synapse has enriched 10 related papers. Consider them for comparative context: